RxSight (RXST) Receivables - Net (2020 - 2026)

RxSight's Receivables - Net history runs 7 years deep, the most recent figure standing at $22.4 million for Q1 2026.

• Quarterly Receivables - Net fell 27.51% year-over-year to $22.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.4 million (down 27.51% YoY) and the FY2025 annual result came in at $23.4 million, down 22.19% from the prior year.
• Receivables - Net was $22.4 million for Q1 2026 at RxSight, down from $23.4 million in the prior quarter.
• Across five years, Receivables - Net topped out at $31.0 million in Q1 2025 and bottomed at $5.6 million in Q1 2022.
• A 5-year average of $19.2 million and a median of $21.6 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net soared 125.34% — and 2026, when it retreated 27.51%.
• RxSight's Receivables - Net stood at $11.0 million in 2022, then jumped by 85.11% to $20.3 million in 2023, then jumped by 48.17% to $30.0 million in 2024, then slipped by 22.19% to $23.4 million in 2025, then slipped by 4.02% to $22.4 million in 2026.
• Business Quant data shows RXST's Receivables - Net at $22.4 million in Q1 2026, $23.4 million in Q4 2025, and $24.2 million in Q3 2025.